irbesartan (avapro) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Irbesartan is an angiotensin receptor blocker (ARB) used mainly for the treatment of hypertension. It was developed by Sanofi Research (now part of Sanofi-Aventis). It is marketed under the trade names Aprovel, Karvea, and Avapro. AVAPRO is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor and no agonist activity.   NCATS

Chemistry

  • SMILES: CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NN=NN5
  • InChIKey: YOSHYTLCDANDAN-UHFFFAOYSA-N
  • Mol. Mass: 428.5294
  • ALogP: 4.78
  • ChEMBL Molecule:
    irbesartan  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$0.0416 - $0.1638

United States

$0.1649 - $8.0124
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( irbesartan (avapro), hydrochlorothiazide (esidrix) - other name: irbesartan hydrochlorothiazide )

Alternative names

1,3-diazaspiro(4.4)non-1-en-4-one, 2-butyl-3-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)- | 2-butyl-3-{[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one | 2-n-butyl-3-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one | aprovel | avapro | bms 186295 | bms-186295 | ibesartan | ifirmasta | irbesartan | irbesartan hcl | irbesartan hydrochloride | irbesartan / hydrochlorothiazide | irbesartan: hydrochlorothiazide | karvea | sabervel | sr 47436 | sr-47436

Organizations (121)

Research & Development (89)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (35)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (45)

Approved Indications (4)


 

Diabetes Mellitus, Type 2

Diabetic Nephropathies

Hypertension

Kidney Failure, Chronic

Experimental Indications - Clinical Trial Phases 1-4 (45)


 

Acute Kidney Injury (Phase 3)

Albuminuria (Phase 4)

Antihypertensive Agents (Phase 4)

Atherosclerosis (Phase 4)

Atrial Fibrillation (Phase 4)

Atrial Function, Left (Phase 4)

Blood Pressure (Phase 2)

Cardiovascular Diseases (Phase 3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Nephropathies ()

Dyslipidemias (Phase 4)

Ehlers-Danlos Syndrome (Phase 3)

Essential Hypertension (Phase 3)

Fasting (Phase 1)

Glomerulonephritis (Phase 2/Phase 3)

Glomerulonephritis, IGA (Phase 3)

Glomerulosclerosis, Focal Segmental (Phase 3)

Healthy Volunteers (Phase 4)

Heart Diseases (Phase 4)

Heart Failure (Phase 4)

Heart Failure, Diastolic (Phase 4)

Hemorrhagic Fever, Ebola (Phase 1/Phase 2)

Hepatitis C, Chronic (Phase 3)

Hypercholesterolemia (Phase 3)

Hyperkalemia (Phase 3)

Hyperlipidemias (Phase 3)

Hypertension ()

Irbesartan (Phase 1)

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 4)

Kidney Transplantation (Phase 3)

Marfan Syndrome (Phase 2)

Metabolic Syndrome (Phase 4)

Myocardial Infarction (Phase 4)

Myocardial Ischemia (Phase 3)

Obesity (Phase 4)

Obesity, Abdominal (Phase 4)

Proteinuria (Phase 2/Phase 3)

Renal Insufficiency, Chronic (Phase 3)

Renin-Angiotensin System (Phase 4)

Sepsis (Phase 3)

Sexual Dysfunction, Physiological (Phase 4)

Stress, Psychological (Phase 2)

Therapeutic Equivalency (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 100
  • # of Trial Organizations: 89

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue